Annals of surgical oncology
August 17, 2026 · via Europe PMC
Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn't Just Ductal.
Beck AC, Carroll EF, Mukhtar RA, Cassidy MR, Flanagan MR, Gamble LA, Erdahl LM.
AI summary — for doctors, generated from the abstract only
An expert panel says invasive lobular breast cancer needs tailored management, including MRI staging and CDH1 testing.
What was studied
Consensus panel at the American Society of Breast Surgeons meeting 2025 with literature review per subtopic.
Key findings
- MRI can improve preoperative staging.
- Imaging limits margin assessment at lumpectomy.
- Neoadjuvant therapy should follow molecular subtype, not histology.
- Genetic testing should include CDH1.
Clinical relevance
Guides multidisciplinary care of ILC.
Who should care
Limitations
Expert consensus with narrative review.
Use MRI, be cautious with margins and include CDH1 testing.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and presents histologically with a unique pattern of discohesive growth. An expert consensus panel was convened at the annual meeting of the American Society of Breast Surgeons to discuss disease specific management considerations and best practice when caring for women with ILC.
Methods
At the annual meeting of the American Society of Breast Surgeons held in Las Vegas, Nevada from April 30 to May 4, 2025, a panel convened to specifically address the intricacies of managing ILC. Panelists completed an independent literature review for each identified subtopic that was summarized and reviewed by panel moderators.
Results
The multidisciplinary management of ILC is nuanced and special considerations are essential to optimize treatment. Magnetic resonance imaging of the breast can improve the accuracy of preoperative staging. Surgeons should account for the limitations of imaging with respect to margin resection in lumpectomy. When considering the application of trials guiding omission of ALND in surgery for ILC, surgeons can rely on several studies that have included subanalyses of patients with ILC confirming safety in appropriately selected patients. Use of neoadjuvant therapy should be based on molecular subtype rather than tumor histology. Genetic testing for patients with ILC should include analysis of CDH1 mutations.
Discussion
Awareness and consideration of nuances around the management of ILC, including those discussed in the present study, can help clinicians provide optimal, evidenced based care to women presenting with ILC.
DOI
10.1245/s10434-026-20368-y
PMID
42606651
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed